Skip to main content
. 2022 Jun 30;13:880258. doi: 10.3389/fmicb.2022.880258

Figure 5.

Figure 5

Compound 8G1 reduced the expression of HTNV-NP proteins at the early stage of HTNV infection. (A) Different administration regimens of compound 8G1 treated the HTNV-infected A549 cells at an MOI of 1.0. Lane a: without compound 8G1 treatment; lane b: compound 8G1 treatment for 2 h pre-infection; lane c: compound 8G1 treatment for 2 h post-infection (hpi); lane d–h: treatment continues from 2 h pre-infection, 2, 12, 24, and 48 hpi to the 96 hpi time point. (B) The representative Western blot staining for HTNV NP protein in the groups with different administration regimens of compound 8G1. (C) The analyzed result of the expression of HTNV-NP protein in groups with different administration regimens of compound 8G1. **p < 0.01 vs. a, n = 3. (D) The representative Western blot staining for HTNV NP protein in the A549 cells without or in the presence of compound 8G1 at different temperatures. (E) The analyzed result of the expression of HTNV NP protein in control or compound 8G1 treatment groups at room temperature (RT) or 37°C.